Literature DB >> 20088889

Progression of initially mild hepatic fibrosis in patients with chronic hepatitis C infection.

M J Williams1, M Lang-Lenton.   

Abstract

A significant number of patients with chronic hepatitis C infection have minimal fibrosis at presentation. Although the short-term outlook for such patients is good, there are limited data available on long-term progression. We assessed the risk of fibrosis progression in 282 patients with chronic hepatitis C with Ishak stage 0 or 1 fibrosis on initial liver biopsy. Progression of fibrosis stage occurred in 118 patients (42%) over a median interval of 52.5 months. Thirteen (5%) progressed to severe (Ishak stage 4 or more) fibrosis. Progression was significantly associated with both age at initial biopsy [odds ratio (OR) for progression of 1.31 per 10 year increase in age] and median alanine transaminase (ALT) levels during follow-up (OR of 1.06 per 10 IU/L increase). There was no significant association with gender, histological inflammatory grade, hepatic steatosis or body mass index. We conclude that hepatitis C with initially mild fibrosis does progress in a substantial proportion of patients and should not be viewed as a benign disease. Early antiviral therapy should be considered in older patients and those with high ALT levels.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 20088889     DOI: 10.1111/j.1365-2893.2009.01262.x

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  6 in total

Review 1.  Systematic review: identifying patients with chronic hepatitis C in need of early treatment and intensive monitoring--predictors and predictive models of disease progression.

Authors:  M A Konerman; S Yapali; A S Lok
Journal:  Aliment Pharmacol Ther       Date:  2014-08-28       Impact factor: 8.171

2.  Improvement of predictive models of risk of disease progression in chronic hepatitis C by incorporating longitudinal data.

Authors:  Monica A Konerman; Yiwei Zhang; Ji Zhu; Peter D R Higgins; Anna S F Lok; Akbar K Waljee
Journal:  Hepatology       Date:  2015-03-20       Impact factor: 17.425

Review 3.  Hepatitis B and C virus hepatocarcinogenesis: lessons learned and future challenges.

Authors:  Michael J Bouchard; Sonia Navas-Martin
Journal:  Cancer Lett       Date:  2010-12-18       Impact factor: 8.679

4.  Relation of IL28B gene polymorphism with biochemical and histological features in hepatitis C virus-induced liver disease.

Authors:  José A Agúndez; Elena García-Martin; María L Maestro; Francisca Cuenca; Carmen Martínez; Luis Ortega; Miguel Carballo; Marta Vidaurreta; Marta Agreda; Gabriela Díaz-Zelaya; Avelina Suárez; Manuel Díaz-Rubio; José M Ladero
Journal:  PLoS One       Date:  2012-05-29       Impact factor: 3.240

5.  Future complications of chronic hepatitis C in a low-risk area: projections from the hepatitis c study in Northern Norway.

Authors:  H Kileng; L Bernfort; T Gutteberg; O S Moen; M G Kristiansen; E J Paulssen; L K Berg; J Florholmen; R Goll
Journal:  BMC Infect Dis       Date:  2017-09-16       Impact factor: 3.090

6.  Association between age at diagnosis and degree of liver injury in hepatitis C.

Authors:  Ana Cláudia de Oliveira; Ana Clara Bortotti; Nathália Neves Nunes; Ibrahin A H El Bacha; Edison Roberto Parise
Journal:  Braz J Infect Dis       Date:  2014-06-04       Impact factor: 3.257

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.